Mankind Pharma Faces Continued Decline Amid Broader Market Volatility and Sector Underperformance

Mankind Pharma, a large-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable decline of 3.07% on June 3, 2025. This drop comes as the stock has underperformed its sector by 2.71%, marking its fourth consecutive day of losses, totaling a decline of 5.15% over this period. The stock reached an intraday low of Rs 2345.05, reflecting a decrease of 2.86% during the trading session.
In terms of moving averages, Mankind Pharma is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Over the past week, the stock has fallen by 4.13%, while its one-month performance shows a slight decline of 1.22%. However, on a longer-term basis, Mankind Pharma has gained 10.70% over the past year, outperforming the Sensex, which has risen by 5.59%.

In the broader market context, the Sensex has faced volatility, reversing sharply after a positive opening and currently trading at 80,707.62, down 0.82%. The index has seen a decline of 1.97% over the last three weeks, while small-cap stocks have shown resilience, with the BSE Small Cap index gaining 0.11% today.